Manufacturing feasibility assessment
5. Verdict
Viable at $150 if limited to gentle intravaginal insemination, with sterile single-use fluid paths, anti-trauma safeguards, and validated labeling; start with a 50-unit clinical usability pilot.
6. Subsystems
- 6.1 Intravaginal applicatorMEDIUM
- 6.2 Semen collection and transfer setLOW
- 6.3 Sterile single-use barrierMEDIUM
- 6.4 Instructions and fertility claimsMEDIUM
- 6.5 Quality and traceabilityMEDIUM
7. Bill of materials
| Item | 100 | 1,000 | 10,000 |
|---|---|---|---|
| 7.1 Medical-grade PP collection cup and funnel | $5.50–$7.50 | $2.60–$3.70 | $1.70–$2.50 |
| 7.2 Graduated PP transfer syringe and plunger | $6.00–$8.50 | $2.80–$4.20 | $1.80–$2.70 |
| 7.3 Soft silicone applicator tip with depth stop | $5.00–$7.50 | $2.40–$3.80 | $1.50–$2.50 |
| 7.4 Applicator body and anti-backflow interface | $4.50–$6.50 | $2.20–$3.20 | $1.40–$2.10 |
| 7.5 Sterile barrier pouch and EO sterilisation | $7.00–$10.00 | $3.80–$5.80 | $2.40–$3.80 |
| 7.6 Printed IFU, discreet carton and tamper seal | $3.50–$5.50 | $1.80–$2.90 | $1.20–$1.90 |
| 7.7 Assembly, visual inspection and lot label | $4.00–$6.00 | $2.20–$3.40 | $1.50–$2.30 |
At 10,000 units, tooling adds about $5.50–$9.50 per kit, or 3.7%–6.3% of $150 retail. Estimated 10k BOM is about $11.50–$17.80, leaving room for conversion, freight, channel margin and compliance.
8. Gates to clear
8.1 [DFM]
A generic syringe-like design can be misused for cervical or intrauterine placement, creating injury risk and a substantially harder regulatory position.
Path: Redesign as a depth-limited, intravaginal-only applicator; conduct ISO 14971 risk analysis, IEC 62366-1 usability work and simulated-use testing with a reproductive-health clinician panel.
8.2 [Certification]
“Highly effective” and fertility-treatment claims can trigger medical-device scrutiny; there is no single global approval and sterile status adds evidence requirements.
Path: Lock intravaginal intended use and non-guaranteed claims, build ISO 13485/ISO 10993/ISO 11607 evidence, then use FDA 513(g) or Q-Submission in the US, EU MDR 2017/745 CE assessment, UK MHRA registration, Health Canada and TGA routes market by market.
8.3 [Tooling]
Low-volume moulding and sterilisation make a polished retail product uneconomic before roughly 1,000 units, despite a healthy 10,000-unit BOM.
Path: Run 100–300 pilot kits using soft tooling or machined fixtures and a qualified EO sterilisation vendor; release hard tooling only after usability results, regulatory classification and a 10,000-unit demand plan are confirmed.
9. Prototype sequence
- 9.1Create a non-sterile functional prototype with a fixed insertion stop, soft tip and collection-to-transfer workflow.Confirms comfort, handling, leakage control and prevention of unintended deep insertion before tooling spend.
- 9.2Conduct clinician-reviewed simulated-use sessions and convert findings into ISO 14971 risk controls and IEC 62366-1 usability requirements.Validates that instructions, geometry and packaging reduce foreseeable misuse and user error.
- 9.3Build a 100–300 unit pilot using medical-grade candidate materials, sterile barrier pouches and a qualified EO sterilisation vendor.Generates real assembly, sterilisation, packaging and shelf-life inputs rather than relying on concept estimates.
- 9.4Obtain US FDA classification feedback and establish the EU MDR technical-file plan before finalising claims and packaging.The required change is claim and intended-use discipline; regulatory route must be known before commercial artwork and mould release.
- 9.5Release production moulds and validation lots after the intravaginal-only design, biocompatibility plan and regional launch sequence are approved.Keeps the project buildable at $150 retail without committing to tooling before the key regulatory gates are closed.
Assessment criteria: J. Tanikella · Engine: GPT-5.6 Terra.
